GlassScriptPhysician profile
Yu Yu Thar
NPI 1083045793
$1,721.66
in general payments reported to CMS, 2019-2025
30 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2021: $298 · 2022: $352 · 2023: $620 · 2024: $14.90 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.83 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $266.96 | 2021-2025 | Eliquis, Opdivo, Camzyos |
| Astrazeneca Pharmaceuticals LP | $198.59 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Pfizer INC. | $180.08 | 2019-2023 | |
| Celgene Corporation | $131.12 | 2023-2025 | Reblozyl, Opdualag |
| Astellas Pharma US INC | $124.79 | 2023-2025 | Padcev, Xtandi |
| Glaxosmithkline, LLC. | $82.96 | 2022-2023 | Ojjaara |
| Genzyme Corporation | $71.55 | 2021-2022 | |
| Janssen Biotech, INC. | $66.76 | 2019-2022 | |
| Array Biopharma INC | $63.48 | 2021-2023 | Braftovi, Lorbrena, Mektovi |
| Genentech USA, INC. | $46.89 | 2019-2025 | Polivy |
| Incyte Corporation | $44.76 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $41.48 | 2022-2023 | Myrisk |
| Genentech, INC. | $39.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.64 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $35.25 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $34.23 | 2025 | Optune Gio |
| Daiichi Sankyo INC. | $33.27 | 2022-2023 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.71 | 2022 | |
| Amgen INC. | $20.31 | 2022 | |
| Lilly USA, LLC | $19.21 | 2021 | |
| Mirati Therapeutics, INC. | $19.07 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $18.75 | 2021 | |
| Deciphera Pharmaceuticals INC. | $16.55 | 2023 | Qinlock |
| Novartis Pharmaceuticals Corporation | $16.07 | 2022 | |
| Abbvie INC. | $15.54 | 2023 | Venclexta |
| Shield Therapeutics INC | $15.21 | 2025 | |
| Alnylam Pharmaceuticals INC. | $14.07 | 2021 | |
| Sumitomo Pharma America, INC. | $13.99 | 2023 | Orgovyx |
| Blueprint Medicines Corporation | $12.50 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Thar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.